1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
1 of 3
FEATURED COMPANIES
- Baxter International Inc.
- GlaxoSmithKline Plc
- Pfizer Inc.
- MORE
Global Motion Sickness Drugs Market: About this market
Motion sickness drugs are pharmaceutical agents that are used to treat nausea and vomiting caused due to motion sickness. The motion sickness drugs market analysis considers sales from both anticholinergics and antihistamines. Our analysis also considers the sales of motion sickness drugs in Asia, Europe, North America, and ROW. In 2018, the anticholinergics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as high demand for hyoscine hydrobromide or scopolamine for the prevention of motion sickness will play a significant role in the anticholinergics segment to maintain its market position. Also, our global motion sickness drugs market report also looks at factors such as availability of over-the-counter (OTC) drugs, availability of drugs in multiple dosage forms and growing tourism worldwide. However, nonpharmacological countermeasures to treat motion sickness, the launch of generics, side effects associated with motion sickness drugs may hamper the growth of the motion sickness drugs industry over the forecast period.
Global Motion Sickness Drugs Market: Overview
Availability of over-the-counter (OTC) drugs
The global motion sickness drugs market is predominantly served by the use of generic drugs that are available both as prescription and OTC drugs. Anticholinergics and antihistamines have been regarded as first-line therapy for suppressing and preventing the symptoms associated with motion sickness. Several antihistamines are available as OTC drugs and can be used by pediatric patients. The availability of these medicines OTC increases their accessibility and affordability and provides patients with the freedom of self-medication for the treatment of symptoms associated with minor illnesses. In addition, the availability of OTC drugs reduces the financial burden associated with medication treatment by eliminating the need for a prescription for the purchase of these drugs. This demand for over-the-counter (OTC) will lead to the expansion of the global motion sickness drugs market at a CAGR of almost 4% during the forecast period.
The advent of nauseogenic information technology
The nauseogenic information technology involves the use of nauseogenic vehicles that help in analyzing an individual's postural stability and can reveal the underlying neural or sensory-motor processes that help in achieving successful body stability. This technology revealed that motion sickness often occurs for a narrow band of frequencies of the imposed oscillation. The frequency band obtained in patients with motion sickness is similar to that produced by postural sway during the natural stance. Further advances in nauseogenic information technology are anticipated to have a positive impact on market growth.
For the detailed list of factors that will drive the global motion sickness drugs market during the forecast period 2019-2023, contact us.
Competitive Landscape
With the presence of several major players, the global motion sickness drugs market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading motion sickness drugs manufacturers, that include Baxter International Inc., GlaxoSmithKline Plc, Johnson & Johnson Services Inc., Pfizer Inc., and Prestige Consumer Healthcare Inc.
Also, the motion sickness drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Motion sickness drugs are pharmaceutical agents that are used to treat nausea and vomiting caused due to motion sickness. The motion sickness drugs market analysis considers sales from both anticholinergics and antihistamines. Our analysis also considers the sales of motion sickness drugs in Asia, Europe, North America, and ROW. In 2018, the anticholinergics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as high demand for hyoscine hydrobromide or scopolamine for the prevention of motion sickness will play a significant role in the anticholinergics segment to maintain its market position. Also, our global motion sickness drugs market report also looks at factors such as availability of over-the-counter (OTC) drugs, availability of drugs in multiple dosage forms and growing tourism worldwide. However, nonpharmacological countermeasures to treat motion sickness, the launch of generics, side effects associated with motion sickness drugs may hamper the growth of the motion sickness drugs industry over the forecast period.
Global Motion Sickness Drugs Market: Overview
Availability of over-the-counter (OTC) drugs
The global motion sickness drugs market is predominantly served by the use of generic drugs that are available both as prescription and OTC drugs. Anticholinergics and antihistamines have been regarded as first-line therapy for suppressing and preventing the symptoms associated with motion sickness. Several antihistamines are available as OTC drugs and can be used by pediatric patients. The availability of these medicines OTC increases their accessibility and affordability and provides patients with the freedom of self-medication for the treatment of symptoms associated with minor illnesses. In addition, the availability of OTC drugs reduces the financial burden associated with medication treatment by eliminating the need for a prescription for the purchase of these drugs. This demand for over-the-counter (OTC) will lead to the expansion of the global motion sickness drugs market at a CAGR of almost 4% during the forecast period.
The advent of nauseogenic information technology
The nauseogenic information technology involves the use of nauseogenic vehicles that help in analyzing an individual's postural stability and can reveal the underlying neural or sensory-motor processes that help in achieving successful body stability. This technology revealed that motion sickness often occurs for a narrow band of frequencies of the imposed oscillation. The frequency band obtained in patients with motion sickness is similar to that produced by postural sway during the natural stance. Further advances in nauseogenic information technology are anticipated to have a positive impact on market growth.
For the detailed list of factors that will drive the global motion sickness drugs market during the forecast period 2019-2023, contact us.
Competitive Landscape
With the presence of several major players, the global motion sickness drugs market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading motion sickness drugs manufacturers, that include Baxter International Inc., GlaxoSmithKline Plc, Johnson & Johnson Services Inc., Pfizer Inc., and Prestige Consumer Healthcare Inc.
Also, the motion sickness drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 3
FEATURED COMPANIES
- Baxter International Inc.
- GlaxoSmithKline Plc
- Pfizer Inc.
- MORE
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
List of Exhibits
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Anticholinergics - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Anticholinergics - Year-over-year growth 2019-2023 (%)
Exhibit 22: Antihistamines - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Antihistamines - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Dosage forms: An overview
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor classification
Exhibit 48: Market positioning of vendors
Exhibit 49: Baxter International Inc. - Vendor overview
Exhibit 50: Baxter International Inc. - Business segments
Exhibit 51: Baxter International Inc. - Organizational developments
Exhibit 52: Baxter International Inc. - Geographic focus
Exhibit 53: Baxter International Inc. - Segment focus
Exhibit 54: Baxter International Inc. - Key offerings
Exhibit 55: Baxter International Inc. - Key customers
Exhibit 56: GlaxoSmithKline Plc - Vendor overview
Exhibit 57: GlaxoSmithKline Plc - Business segments
Exhibit 58: GlaxoSmithKline Plc - Organizational developments
Exhibit 59: GlaxoSmithKline Plc - Geographic focus
Exhibit 60: GlaxoSmithKline Plc - Segment focus
Exhibit 61: GlaxoSmithKline Plc - Key offerings
Exhibit 62: GlaxoSmithKline Plc - Key customers
Exhibit 63: Johnson & Johnson Services Inc. - Vendor overview
Exhibit 64: Johnson & Johnson Services Inc. - Business segments
Exhibit 65: Johnson & Johnson Services Inc. - Organizational developments
Exhibit 66: Johnson & Johnson Services Inc. - Geographic focus
Exhibit 67: Johnson & Johnson Services Inc. - Segment focus
Exhibit 68: Johnson & Johnson Services Inc. - Key offerings
Exhibit 69: Johnson & Johnson Services Inc. - Key customers
Exhibit 70: Pfizer Inc. - Vendor overview
Exhibit 71: Pfizer Inc. - Business segments
Exhibit 72: Pfizer Inc. - Organizational developments
Exhibit 73: Pfizer Inc. - Geographic focus
Exhibit 74: Pfizer Inc. - Segment focus
Exhibit 75: Pfizer Inc. - Key offerings
Exhibit 76: Pfizer Inc. - Key customers
Exhibit 77: Prestige Consumer Healthcare Inc. - Vendor overview
Exhibit 78: Prestige Consumer Healthcare Inc. - Business segments
Exhibit 79: Prestige Consumer Healthcare Inc. - Organizational developments
Exhibit 80: Prestige Consumer Healthcare Inc. - Geographic focus
Exhibit 81: Prestige Consumer Healthcare Inc. - Segment focus
Exhibit 82: Prestige Consumer Healthcare Inc. - Key offerings
Exhibit 83: Prestige Consumer Healthcare Inc. - Key customers
Exhibit 84: Validation techniques employed for market sizing
Exhibit 85: Definition of market positioning of vendors
PART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
- Market segmentation by product
- Comparison by product
- Anticholinergics - Market size and forecast 2018-2023
- Antihistamines - Market size and forecast 2018-2023
- Market opportunity by product
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
- Advent of nauseogenic information technology
- Rising trend of virtual reality
- Growing research in psychosomatic disorders
- Overview
- Landscape disruption
- Competitive scenario
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Baxter International Inc.
- GlaxoSmithKline Plc
- Johnson & Johnson Services Inc.
- Pfizer Inc.
- Prestige Consumer Healthcare Inc.
- Research methodology
- List of abbreviations
- Definition of market positioning of vendors
List of Exhibits
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Anticholinergics - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Anticholinergics - Year-over-year growth 2019-2023 (%)
Exhibit 22: Antihistamines - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Antihistamines - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Dosage forms: An overview
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor classification
Exhibit 48: Market positioning of vendors
Exhibit 49: Baxter International Inc. - Vendor overview
Exhibit 50: Baxter International Inc. - Business segments
Exhibit 51: Baxter International Inc. - Organizational developments
Exhibit 52: Baxter International Inc. - Geographic focus
Exhibit 53: Baxter International Inc. - Segment focus
Exhibit 54: Baxter International Inc. - Key offerings
Exhibit 55: Baxter International Inc. - Key customers
Exhibit 56: GlaxoSmithKline Plc - Vendor overview
Exhibit 57: GlaxoSmithKline Plc - Business segments
Exhibit 58: GlaxoSmithKline Plc - Organizational developments
Exhibit 59: GlaxoSmithKline Plc - Geographic focus
Exhibit 60: GlaxoSmithKline Plc - Segment focus
Exhibit 61: GlaxoSmithKline Plc - Key offerings
Exhibit 62: GlaxoSmithKline Plc - Key customers
Exhibit 63: Johnson & Johnson Services Inc. - Vendor overview
Exhibit 64: Johnson & Johnson Services Inc. - Business segments
Exhibit 65: Johnson & Johnson Services Inc. - Organizational developments
Exhibit 66: Johnson & Johnson Services Inc. - Geographic focus
Exhibit 67: Johnson & Johnson Services Inc. - Segment focus
Exhibit 68: Johnson & Johnson Services Inc. - Key offerings
Exhibit 69: Johnson & Johnson Services Inc. - Key customers
Exhibit 70: Pfizer Inc. - Vendor overview
Exhibit 71: Pfizer Inc. - Business segments
Exhibit 72: Pfizer Inc. - Organizational developments
Exhibit 73: Pfizer Inc. - Geographic focus
Exhibit 74: Pfizer Inc. - Segment focus
Exhibit 75: Pfizer Inc. - Key offerings
Exhibit 76: Pfizer Inc. - Key customers
Exhibit 77: Prestige Consumer Healthcare Inc. - Vendor overview
Exhibit 78: Prestige Consumer Healthcare Inc. - Business segments
Exhibit 79: Prestige Consumer Healthcare Inc. - Organizational developments
Exhibit 80: Prestige Consumer Healthcare Inc. - Geographic focus
Exhibit 81: Prestige Consumer Healthcare Inc. - Segment focus
Exhibit 82: Prestige Consumer Healthcare Inc. - Key offerings
Exhibit 83: Prestige Consumer Healthcare Inc. - Key customers
Exhibit 84: Validation techniques employed for market sizing
Exhibit 85: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 3
LOADING...
4 of 3
- Baxter International Inc.
- GlaxoSmithKline Plc
- Johnson & Johnson Services Inc.
- Pfizer Inc.
- Prestige Consumer Healthcare Inc.
Note: Product cover images may vary from those shown
